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ScienceDirectGasotransmitters fulfill important roles in cellular homeostasis
having been linked to various pathologies, including
inflammation and cardiovascular diseases. In addition to the
known pathways mediating the actions of gasotransmitters,
their effects in regulating mitochondrial function are emerging.
Given that mitochondria are key organelles in energy
production, formation of reactive oxygen species and
apoptosis, they are important mediators in preserving health
and disease. Preserving or restoring mitochondrial function by
gasotransmitters may be beneficial, and mitigate pathogenetic
processes. In this review we discuss the actions of
gasotransmitters with focus on their role in mitochondrial
function and their therapeutic potential.
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Introduction
Gasotransmitters are small, chemically reactive, mole-
cules with short half-lives that played crucial roles in
the development of life. Nitric oxide (NO) and carbon
monoxide (CO) were the first described and best-known
gasotransmitters, with hydrogen sulfide (H2S) being dis-
covered more recently. Given that gasotransmitterswww.sciencedirect.com diffuse freely across cellular membranes, they can poten-
tially regulate a broad range of important cellular func-
tions throughout the body. These include regulating
vascular tone [1], neuromodulation [2], paracrine cell
signaling [3], and mitochondrial function [4]. Because
of their effect on key cellular functions, any disturbance
in their availability is linked to a variety of pathological
conditions. The mitochondrion is an organelle targeted
by gasotransmitters where they modulate mitochondrial
function, including adenosine triphosphate (ATP) pro-
duction, reactive oxygen species (ROS) formation and
initiation of apoptotic cascades, which are all important
mediators in inflammation and disease.
The present review provides an overview of recent findings
on the role of gasotransmitters modulating inflammation,
disease pathogenesis, and mitochondrial function. It also
explores avenues to target enzyme activity or supply gaso-
transmitter donors as therapeutic interventions.
Gasotransmitter synthesis and bioavailability
Several enzymes can produce gasotransmitters. NO is
formed by the conversion of L-arginine to L-citrulline,
an oxidative process regulated by three subtypes of nitric
oxide synthases (NOS) with different expression levels in
different cells: neuronal (nNOS), endothelial (eNOS) and
inducible (iNOS) nitric oxide synthase. Within a cell,
iNOS and nNOS are mainly cytosolic, although nuclear
localization of nNOS in rat astrocytes has been reported
[5]. eNOS is membrane-bound, to facilitate release of NO
to the extracellular environment.
CO is synthesized by conversion of heme to biliverdin
through heme oxygenase (HO), an enzyme that occurs in
three different isoforms: HO-1, HO-2 and HO-3. HO is
mainly located in the endoplasmic reticulum (ER), but
similar to NOS, HO is also present in the mitochondria [6].
H2S is derived from cysteine by enzymatic reactions cata-
lyzed by mainly cytosolic cystathionine b-synthase (CBS),
cystathionine g-lyase (CSE) and cysteine aminotransferase
(CAT). However, in line with the mitochondrial NO and
CO, CBS and CSE translocate to mitochondria during
cellular stress such as hypoxia [7]. Additionally, H2S is
produced directly within mitochondria by 3-mercaptopyr-
uvate sulfur-transferase (3MST) [8]. Summarizing, the
production of gasotransmitters is regulated by differentCurrent Opinion in Pharmacology 2019, 45:87–93
88 Cardiovascular and renalenzymes, of which spatial expression patterns differ
between organs and cell types. All gasotransmitters can
be produced near or inside mitochondria, which indicates a
potentially important role of these molecules in mitochon-
drial function.
A simplified overview of the synthesis and bioavailability
of gasotransmitters is outlined in Figure 1.
Gasotransmitters in physiology and disease
A plethora of physiological effects of gasotransmitters have
been documented. For instance, gasotransmitters, both via
direct intracellular effects and released in the extracellular
space, play an important role in regulation of vascular tone,
reduce oxidative stress, and induce angiogenesis [9]. More
specifically, CO is involved in regulation of endothelial cell
survival and proliferation, protection from ischemia-reper-
fusion injury (IRI), vasorelaxation and inhibition of pro-
inflammatory responses. HO-1 acts as an inflammation-
neutralizing factor regulated by nuclear-factor-E2-related
factor-2 (Nrf2), as observed in lung inflammation after
intestinal IRI [10]. NO regulates numerous intra-cellular
and inter-cellular processes such as platelet aggregation,
endothelial adhesion of leukocytes and relaxation of smooth
muscle cells. Moreover, iNOS activated by nuclear-factor-
kappa B (NF-kB) activation and signal-transducer-and-acti-
vator-of-transcription-1a (STAT-1a) results in elevated NO
levels and represents an important component in the inflam-
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A general overview of the cellular synthesis and bioavailability of
gasotransmitters within a cell.
3MST (3-mercaptopyruvate sulfur-transferase), CBS (cystathionine
b-synthase), CSE, (cystathionine g-lyase) and CAT (cysteine
aminotransferase) produce H2S (hydrogen sulfide). HO (heme
oxygenase) produces CO (carbon monoxide). NO (Nitric oxide) is
produced by NOS (nitric oxide synthase).
Current Opinion in Pharmacology 2019, 45:87–93 nitrosative stress, is correlated with the severity of liver
disease in mice [12]. In contrast, the anti-inflammatory
action of NO is revealed in iNOS-knockout high-fat-diet
fed mice that show an increased inflammation leading to
liver fibrosis [13]. These data indicate that NO harbors
potential to exert both pro-inflammatory and anti-inflamma-
tory functions, most likely in a dose-dependent manner. H2S
has important anti-inflammatory and antioxidant potential,
and causes relaxation of blood vessels [14]. H2S protects
endothelial cells from lipopolysaccharide (LPS)-induced
inflammation by blocking NF-kB transactivation [15]. In
addition, exogenous H2S treatment decreased inflammation
and IRI following intestinal ischemia, whereas eNOS
knockout mice were not protected by exogenous H2S.
These data suggest that H2S shows protective effects in
an eNOS-dependent manner [16]. NADPH oxidase (Nox),
a mitochondrial source of ROS, is a key-signaling pathway
responsible for the increased inflammatory response of
macrophages in vitro and in septic mice [17,18], which
could be ameliorated by endogenous H2S.
Reduced bioavailability of gasotransmitters has been
observed in vascular pathology [19], aging [20] and
aging-related pathologies [21], renal pathology [22] and
diabetes [23] (Figure 2). These associations suggest
causality between gasotransmitter bioavailability and
disease pathogenesis.
The various pathways, in which gasotransmitters are
involved in disease pathogenesis and inflammation
become of even more interest when looking at mitochon-
drial dysfunction, for example, in sepsis. Brealey et al.
demonstrated lowered ATP levels, overproduction of
NO, and mitochondrial dysfunction in skeletal muscle
biopsies of septic patients [24]. Using H2S and CO,
potentiation of mitochondrial function could preserve
tissue function during sepsis [25]. The authors suggested
various therapeutic interventions to increase exogenous
and endogenous H2S production, to specifically inhibit
iNOS and to stimulate HO-1 activity, in order to target
mitochondrial pathways in sepsis and inflammation.
A schematic overview of some of the involved pathways is
shown in Figure 2.
Mitochondrial aspects of gasotransmitters
Mitochondria, ‘the powerhouses of the cell’ represent the
main source of energy using oxidative phosphorylation,
but also modulate important regulatory and signaling
processes. In oxidative phosphorylation, mitochondria
oxidize substrates via the electron transport chain
(ETC) to create a proton gradient, which is used to drive
the ATP synthesis. Gasotransmitters regulate this pro-
cess, supporting normal physiology.
NO, CO, and H2S all reduce the ETC activity via
inhibition of cytochrome c oxidase (COX) in a reversible,www.sciencedirect.com
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A schematic overview of some of the disease-related pathways gasotransmitters are involved in.
All three gasotransmitters, H2S (hydrogen sulfide), CO (carbon monoxide) and NO (nitric oxide) showed mitigating effects in a variety of diseases.
IRI = ischemia reperfusion injury.fast-acting and dose-dependent manner [1]. Accordingly,
gasotransmitters may preserve normal ETC function.
Indeed, administration of NO and CO protected mito-
chondria, presumably by decreasing ROS production,
during hemorrhagic shock [26]. Furthermore, upregula-
tion of HO-1 normalized mitochondrial function and
decreased ROS formation in IRI [27]. Also H2S protects
the ETC through different mechanisms [28]. In line with
this, CSE knockout mice are more susceptible to cerebral
IRI compared to controls; which could be reversed using
exogenous H2S [29]. Interestingly, in contrast to NO and
CO, H2S can act as hydrogen donor and functions as
substrate for mitochondrial respiration [30].
High-dose treatment with CO, NO or H2S can almost
completely inhibit mitochondrial activity, and especially
H2S harbors the potential to suppress metabolism in a safe
manner: the induction of a hypometabolic state [31,32].
This hibernation-like state has is protective to IRI,
thereby having therapeutic potential in, for example,
organ transplantation [33].www.sciencedirect.com Besides direct effects on mitochondrial function,
gasotransmitters play an important role in ROS scaveng-
ing. NO is a potent antioxidant by virtue of its fast
reaction with hydroxyl radicals, superoxides and lipid
peroxides [34]. Exogenous H2S administration protected
cardiac tissue from ROS damage in a myocardial injury
rat model [35].
In addition to the direct scavenging potential, gasotrans-
mitters are also important in the activation of scavenging
pathways, such as Nrf2 and glutathione (GSH). Kelch-
like-ECH-associated-protein-1 (Keap1) serves as a nega-
tive regulator of Nrf2, during stress-free physiology, by
binding to Nrf2 in the cytoplasm and promoting degra-
dation of Nrf2. Cellular stress provoked by ROS, inacti-
vates Keap1 and therefore stabilizes Nrf2, allowing trans-
location to the nucleus and activation of its target: the
antioxidant-response-element (ARE) [36,37]. H2S can
promote Keap1-dependent Nrf2 stabilization, which
facilitates Nrf2 translocation into the nucleus [38].
Indeed, exogenous NaHS administration to a diabeticCurrent Opinion in Pharmacology 2019, 45:87–93
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A simplified overview of the interactions between gasotransmitters and mitochondria.
ETC = electron transport chain, ROS = reactive oxygen species, GSH = glutathione, IRI = ischemia reperfusion injury.stressed rat model resulted in increased nuclear Nrf2
levels, activation of superoxide dismutase (SOD) and
limited the numbers of apoptotic cells [39]. Besides
increasing GSH production, H2S is thought to redistrib-
ute GSH into the mitochondria to directly scavenge
mitochondrial-produced superoxides [40]. CO exposure
in transplanted rat lungs protected against apoptosis,
likely via increased SOD activity and decreased ROS-
induced damage [41].
Another important pathway that gasotransmitters are
involved in is the opening of the mitochondrial perme-
ability transition pore (mPTP). Full opening of these
pores in response to several factors including excessive
ROS production and calcium-overload, results in a loss of
mitochondrial membrane potential and reduced oxidative
phosphorylation, mitochondrial swelling and a burst of
ROS, eventually leading to necrosis or apoptosis [42].
Exogenous H2S inhibits apoptosis via blockade of mPTP
formation and cytochrome c (cyt c) release [43]. Apoptosis
can be activated by the Bcl2-family, cyt c release
and caspase activation. Both NO and CO are known to
suppress the Bcl2-family and caspase activation [44,45].
These findings indicate that gasotransmitters have an
important role in the cellular energetic state and apoptosis
by regulating several mitochondrial-related and ROS-
related actions, as outlined in Figure 3.Current Opinion in Pharmacology 2019, 45:87–93 Treatment perspectives
Exogenous administration of gasotransmitters is an
emerging therapeutic option. The oldest and most used
donor is the acute NO donor nitroglycerin, causing vaso-
dilation and relieving acute pain during angina pectoris.
Another clinically relevant NO donor in current use is
sodium nitroprusside (SNP), also playing an important
role in vasorelaxation. On the basis of these successes,
several NO donors were synthesized, among which com-
bined therapeutics, such as NO-NSAID [46]. Addition-
ally, downstream NO-modulating drugs were tested, for
example, the phosphodiesterase 5 (PDE5) inhibitor
sildenafil [47]. Sildenafil treatment increased activity of
the NO/cGMP pathway and protected from oxidative
damage and apoptosis in diabetes [48] and cardiovascular
dysfunction [49]. In contrast, recent findings in pregnant
women with fetal growth restriction revealed detrimental
effects of sildenafil treatment [50]. In line with the
functions of CO, carbon monoxide-releasing-molecules
(CORMs) have anti-apoptotic, anti-inflammatory, and
antioxidant effects [51]. The fast releasing H2S donors
NaHS and Na2S are widely used in the experimental
setting and induce a hypometabolic state [32]. However,
these donors are not suitable for precise and sustained
administration. A potential alternative can be found in
thiosulfate (STS). STS showed positive effects on hyper-
tension and renal injury [52]. The potential of STS on
reducing cardiac ischemia is now being clinically tested.www.sciencedirect.com
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Table 1
Overview of different exogenous gasotransmitter donors
Compound Chemistry Characteristics
GYY4137 [58] C11H16NO2PS2C4H10NO Slow-releasing H2S donor
AP39 [54,59] C37H38O2PS3 Mitochondria-targeted H2S donor
DATS–MSN [53,60] C6H10S3 [DATS] Trisulfide (DATS) conjugated to a
mesoporous silica nanoparticles
(MSN) carrier
ZYZ-803 [56,57] C20H23N3O6S Slow-releasing NO/H2S hybrid moleculeRecently, to exploit the protective properties of H2S,
slow-releasing H2S molecules have been synthesized,
including morpholin-4-ium 4 methoxyphenyl (morpho-
lino) phosphinodithioate (GYY4137), 10-oxo-10-[4-
(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy]decyl]triphenyl-
phosphonium (AP39), and a natural garlic-derived poly-
sulfide compound–diallyl trisulfide (DATS) conjugated to
a mesoporous silica nanoparticles (MSN) carrier (DATS–
MSN) (Table 1). Whereas GYY4137 is not specifically
targeted, AP39 is a mitochondria-targeted H2S donor, with
potent protective effects in an organ transplantation model
[54]. DATS–MSN shows superior anti-apoptotic, anti-
oxidant and anti-inflammatory abilities as compared to
NaHS [53]. Also ROS-triggered H2S donors [55] and
slow-releasing NO/H2S hybrid molecules have been
developed (e.g. ZYZ-803) [56] (Table 1), their use showing
promising protective effects against heart failure [57].
Conclusion
Gasotransmitters play a key role in the pathogenesis of
various diseases, with a unifying role in preservation
of mitochondrial function. H2S, CO, and NO contribute
to maintaining normal mitochondrial function and show
a broad variety of potential therapeutic properties: influ-
encing ETC activity, direct scavenging of ROS, activa-
tion of scavenging pathways, and attenuation of apoptosis.
Accordingly, gasotransmitters are potential efficacious
drugs and this insight has led to the synthesis of long-
lasting and slow-releasing donors. Although promising
results have been obtained in experimental diseasewww.sciencedirect.com models, these compounds have not been extensively
tested in the clinic. This urges the need for more exten-
sive research and new compounds. A mitochondrial tar-
geted combination of H2S–NO–CO donor is an attractive
concept to protect mitochondria from noxious insults;
whether this concept is actually feasible remains to be
seen in the near future.
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